Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 466, Issue 3, Pages 323-329Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(03)01570-X
Keywords
colitis; adenosine; cytokine; chemokine
Categories
Funding
- NIDDK NIH HHS [R43 DK 57379] Funding Source: Medline
Ask authors/readers for more resources
This study evaluated the effects of the adenosine A(3) receptor agonist, N-6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA), in two murine models of colitis, the dextran sodium sulphate-induced colitis and the spontaneous colitis found in interleukin-10 gene deficient mice. IB-MECA was given orally twice a day at a dose of either 1 or 3 mg/kg/day. Evaluation of colon damage and inflammation was determined grossly (body weight, rectal bleeding) and biochemically (colon levels of myeloperoxidase, malondialdehyde, chemokines and cytokines). There was significantly increased inflammatory cell infiltration into the colon associated with an increase in colon levels of cytokines and chemokines; with subsequent free radical related damage in both dextran sodium sulphate-induced colitis and 10-week-old interieukin-10(-/-) mice. IB-MECA protected in both models against the colitis induced inflammatory cell infiltration and damage and attenuated the increases in colon inflammatory cytokine and chemokine levels. Thus activation of the adenosine A(3) receptor is effective in protecting against colitis. (C) 2003 Elsevier Science B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available